Calidi Biotherapeutics
CLDI
21 hedge funds and large institutions have $2.83M invested in Calidi Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
110% more funds holding
Funds holding: 10 → 21 (+11)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more ownership
Funds ownership: 0% → 0% (+0%)
20% less capital invested
Capital invested by funds: $3.54M → $2.83M (-$714K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$228K |
| 2 |
Millennium Management
New York
|
+$228K |
| 3 |
GL
Governors Lane
New York
|
+$210K |
| 4 |
SAMC
Spectrum Asset Management (California)
Newport Beach,
California
|
+$189K |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$416K |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$326K |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$30.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$332 |
CLDI Hedge Fund Activity: Q4 2023 in Review
21 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q4 2023, worth a combined $2.83M — down 20% from $3.54M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CLDI positions and 2 closed out — a net gain of 11 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $228K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $416K sold.
- 21 institutional investors held Calidi Biotherapeutics (CLDI) as of Q4 2023, up from 10 in Q3 2023.
- Funds reported $2.83M of Calidi Biotherapeutics stock for Q4 2023, down 20% quarter-over-quarter.
- 13 funds opened new Calidi Biotherapeutics positions in Q4 2023 and 2 closed out, a net change of +11 holders.
- The largest Calidi Biotherapeutics buyer in Q4 2023 was Geode Capital Management, an estimated $228K added.
- The largest Calidi Biotherapeutics seller in Q4 2023 was Highbridge Capital Management, an estimated $416K sold.
Based on aggregated 13F filings for Q4 2023.